Todas las fotos(1)

Documentos

Y0001480

Sulfadiazine

Name: Sulfadiazine
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

Sulfadiazine, 4-Amino-N-(2-pyrimidinyl)benzenesulfonamide, N¹-(Pyrimidin-2-yl)sulfanilamide

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización

Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):

C₁₀H₁₀N₄O₂S

Número de CAS:

68-35-9

Peso molecular:

250.28

Beilstein/REAXYS Number:

6733588

MDL number:

MFCD00006065

UNSPSC Code:

41116107

PubChem Substance ID:

329831448

NACRES:

NA.24

grade

pharmaceutical primary standard

API family

sulfadiazine

manufacturer/tradename

EDQM

mp

253 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

Nc1ccc(cc1)S(=O)(=O)Nc2ncccn2

InChI

1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)

InChI key

SEEPANYCNGTZFQ-UHFFFAOYSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Patrones de las farmacopeas y de los institutos metrológicos

Patrones de referencia analítica | Sigma-Aldrich

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Sulfadiazine for identification of impurity F EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Referencia del producto

Descripción

Precios

signalword

Warning

hcodes

H302,H361d,H411

pcodes

P202 - P264 - P273 - P280 - P301 + P312 - P308 + P313

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 2 - Repr. 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 2

Choose from one of the most recent versions:

Certificados de análisis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome.

K Becker et al.

Medicine, 75(4), 185-194 (1996-07-01)

We performed a computerized search on sulfadiazine-associated nephrotoxicity reported in human immunodefiency virus (HIV)-infected patients in the international literature. Including an original case report, we summarized 35 acquired immunodefiency syndrome (AIDS) patients from 1987 to 1995 in an analysis comparing

[Acute kidney failure caused by sulfadiazine stones. A complication of the therapy of toxoplasmosis in AIDS].

U Kronawitter et al.

Deutsche medizinische Wochenschrift (1946), 118(46), 1683-1686 (1993-11-19)

A 45-year-old man with AIDS was treated for a recurrence of cerebral toxoplasmosis with sulphadiazine, 4 g, and pyrimethamine, 75 mg, daily. Owing to a lack of appetite and dysphagia he drank rather little water during the first week of

Sulfadiazine-induced nephrolithiasis in children.

Charlotte Catalano-Pons et al.

Pediatric nephrology (Berlin, Germany), 19(8), 928-931 (2004-06-19)

Sulfadiazine-associated urinary calculi have been described in HIV-positive adult patients but rarely in children. We report two pediatric cases of sulfadiazine-induced nephrolithiasis and review 45 adult cases from the literature. One had a hyper-IgM syndrome and was treated with sulfadiazine

Sulfadiazine crystalluria revisited. The treatment of Toxoplasma encephalitis in patients with acquired immunodeficiency syndrome.

D I Simon et al.

Archives of internal medicine, 150(11), 2379-2384 (1990-11-01)

Toxoplasma gondii encephalitis is an important opportunistic infection in the acquired immunodeficiency syndrome, estimated to occur in 20,000 to 40,000 patients with acquired immunodeficiency syndrome in the United States by 1991. The combination of sulfadiazine and pyrimethamine is regarded as

Silver sulfadiazine: an antibacterial agent for topical use in burns. A review of the literature.

S Hoffmann

Scandinavian journal of plastic and reconstructive surgery, 18(1), 119-126 (1984-01-01)

Topical antibacterial treatment is of major importance in the burn patient. Silver sulfadiazine is an effective agent with low toxicity and few side effects. Deposition of silver in tissues, and absorption of sulfadiazine are both minimal. Present and future problems

Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico